ClinicalTrials.gg
Not yet recruitingNCT07186504Updated Sep 22, 2025

Adapted Physical Activity and Pelvic Floor Function for Pelvic Girdle Pain During Pregnancy

An interventional study of Adapted Physical Activity and Pelvic Floor Rehabilitation in Pelvic Girdle Pain, Pregnancy and Pelvic Floor Dysfunctions, sponsored by Haute Ecole de Santé Vaud. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Haute Ecole de Santé Vaud · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Pelvic girdle pain (PGP) is a common condition during pregnancy, affecting up to two-thirds of women. It can cause significant discomfort, limit daily activities, and reduce quality of life. Current treatment options are limited, and many women continue to experience pain throughout pregnancy and even after childbirth.

This study will evaluate whether a structured program of adapted physical activity, with additional individualized pelvic floor rehabilitation when needed, can reduce pelvic girdle pain and improve function during pregnancy. The intervention consists of weekly 60-minute sessions of adapted physical activity, led by a pelvic health physiotherapist, from inclusion until 36-38 weeks of gestation. The exercises focus on lumbopelvic stability, mobility, strengthening, and safe aerobic activity. If a participant presents with pelvic floor dysfunction, individualized rehabilitation may be added in parallel.

Participants will be randomly assigned to either the intervention group (adapted physical activity ± pelvic floor rehabilitation) or a control group. The control group will receive standard pregnancy follow-up care plus a validated flyer with international recommendations on physical activity during pregnancy but without supervised sessions.

The primary outcomes are pain intensity and functional impact of PGP, measured using the Visual Analog Scale (VAS) and the Pelvic Girdle Questionnaire (PGQ). Secondary outcomes include self-reported physical activity, pelvic symptoms, pelvic floor function, adherence to the intervention, and acceptability of the program.

A total of 40 pregnant women will be enrolled at Hospital La Tour in Geneva, Switzerland. Assessments will take place at three time points: inclusion (≤27 weeks of gestation), late pregnancy (36-38 weeks), and 3 months after delivery.

The study is expected to provide new evidence on the benefits of integrating pelvic floor functionality into physical activity programs for pregnant women with PGP. If effective, this approach could inform clinical practice and improve care for women during pregnancy

Read the detailed description

Background and Rationale

Pregnancy induces substantial morphological, hormonal, and biomechanical changes that increase the risk of musculoskeletal pain, particularly pelvic girdle pain (PGP). Up to 63% of pregnant women experience PGP, which may significantly affect mobility, quality of life, and psychological well-being. Although international guidelines, including those of the American College of Obstetricians and Gynecologists (ACOG), recommend physical activity during pregnancy, few interventions specifically target PGP, and the role of pelvic floor function has been largely overlooked.

The pelvic floor contributes to lumbopelvic stability through myofascial connections and motor control. Dysfunction of the pelvic floor muscles is frequently observed in women with PGP, with symptoms such as hypertonicity, poor endurance, and ineffective contractions. Evidence suggests an association between pelvic floor dysfunction and pelvic pain, but no trial to date has combined adapted physical activity with targeted pelvic floor rehabilitation in pregnant women with PGP.

Objectives

The primary objective of this exploratory randomized controlled trial is to evaluate the effect of a combined intervention (adapted physical activity with optional individualized pelvic floor rehabilitation) on pain intensity and functional impact of PGP during pregnancy.

Secondary objectives include:

  • To assess the effect of the intervention on pelvic symptoms and pelvic floor functionality.
  • To explore the relationship between pelvic floor dysfunction and the course of PGP.
  • To evaluate adherence and acceptability of the intervention program.

Study Design

This is a monocentric, randomized, controlled, open-label exploratory trial conducted at Hospital La Tour in Geneva, Switzerland. Forty pregnant women with clinically confirmed PGP will be randomly assigned (1:1) to an intervention group or a control group. Randomization will be stratified by gestational age and baseline pain intensity.

Intervention group: Weekly adapted physical activity sessions in group format (minimum 9 sessions, 60 minutes each), from enrollment until 36-38 weeks of gestation. Sessions alternate between land and pool settings and include lumbopelvic stabilization, core and multifidus strengthening, mobility, and cardiorespiratory training. Women identified with pelvic floor dysfunction at baseline (via the Pelvic Floor Distress Inventory, PFDI-20) will also be offered up to 9 sessions of individualized pelvic floor rehabilitation.

Control group: Standard prenatal follow-up and a flyer with evidence-based recommendations on safe physical activity during pregnancy. No supervised sessions are provided.

Study Population

Eligible participants are pregnant women ≤27 weeks of gestation with clinically confirmed PGP of moderate to severe intensity (VAS ≥3/10). Diagnosis requires typical pain localization and at least 3 positive clinical tests (e.g., P4 test, Patrick FABER, Menell, ASLR). Exclusion criteria include isolated low back pain without pelvic involvement or any medical contraindication to exercise during pregnancy.

Outcomes

  1. Primary outcomes:

    • Pain intensity measured by the Visual Analog Scale (VAS, 0-10 cm).
    • Functional impact of PGP measured by the Pelvic Girdle Questionnaire (PGQ, 25 items, score 0-100).
  2. Secondary outcomes:

    • Physical activity (Pregnancy Physical Activity Questionnaire, PPAQ).
    • Pelvic symptoms (Pelvic Floor Distress Inventory, PFDI-20).
    • Pelvic floor function (PERFECT scheme by digital palpation).
    • Adherence to intervention (≥75% of sessions attended).
    • Acceptability (post-intervention questionnaire with Likert scales).

Assessments occur at baseline (≤27 weeks), late pregnancy (36-38 weeks), and 3 months postpartum.

Sample Size and Statistical Considerations

Sample size (n=40, 20 per group) was determined based on detecting a clinically meaningful reduction in VAS pain scores, with α=0.05, 95% power, and an expected large effect size (d=0.8). Data will be analyzed on an intention-to-treat basis using descriptive statistics, parametric or non-parametric tests as appropriate, and mixed linear models including relevant covariates (e.g., parity, baseline scores).

Duration and Timeline

The project will last 27 months in total. Enrollment will begin in September 2025 and end in December 2026. The last postpartum follow-up will occur in March 2027, and the study will close in October 2027. Individual participation lasts approximately 6-8 months.

Ethical Considerations

The study is categorized as minimal risk (Category A under Swiss ClinO). All interventions are non-invasive, adapted to pregnancy, and consistent with international standards for prenatal physiotherapy. Approval will be obtained from the Commission Cantonale d'Éthique de la Recherche sur l'être humain (CCER), affiliated with swissethics. Participation is voluntary, and women may withdraw at any time without affecting their standard care. Data will be managed securely in REDCap with strict confidentiality measures.

Significance

This trial will generate new evidence on a comprehensive approach integrating adapted physical activity with pelvic floor rehabilitation for managing pelvic girdle pain in pregnancy. If effective, it could inform physiotherapy practice and contribute to international guidelines, ultimately improving maternal health and quality of life.

02

Conditions studied

  • Pelvic Girdle Pain
  • Pregnancy
  • Pelvic Floor Dysfunctions

Browse trials for

Keywords

  • Pregnancy-related pelvic girdle pain
  • Prenatal pelvic pain
  • Pelvic floor function
  • Pelvic floor rehabilitation
  • Adapted physical activity
  • Prenatal exercise
  • Physiotherapy in pregnancy
  • Prenatal musculoskeletal pain
  • Maternal health
  • Randomized controlled trial
03

In context

Pelvic Girdle Pain

63 studies on the registry are indexed under Pelvic Girdle Pain; 14 are open to participants now.

This study's planned enrollment of 40 is below the median of 53 across 45 interventional studies indexed under Pelvic Girdle Pain.

Browse Pelvic Girdle Pain studies →

Lead sponsor

Haute Ecole de Santé Vaud is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged ≥18 years
  • Gestational age ≤27 weeks at enrollment
  • Clinically confirmed pelvic girdle pain, defined as:
  • Pain localized between the posterior iliac crest and the gluteal fold, particularly around the sacroiliac joints and/or pubic symphysis, Pain intensity ≥3/10 on Visual Analog Scale (VAS), At least 3 positive clinical tests among: Posterior Pelvic Pain Provocation (P4) test, Patrick's FABER, Menell's test, Active Straight Leg Raise (ASLR), and palpation of long dorsal sacroiliac ligament or symphysis pubis
  • Ability to understand and provide written

Exclusion criteria

Exclusion Criteria:

  • Isolated low back pain without pelvic involvement
  • to exercise during pregnancy (e.g., severe preeclampsia, placenta previa after 26 weeks, risk of preterm labor, ruptured membranes, significant cardiac or pulmonary disease)
  • Neurological, rheumatologic, or orthopedic conditions that may interfere with participation
  • Insufficient French language proficiency to understand questionnaires and instructions
  • Participation in another interventional study that could affect outcomes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Adapted Physical Activity with or without Pelvic Floor Rehabilitation

    Participants attend weekly 60-minute sessions of adapted physical activity, from enrollment (≤27 weeks gestation) until 36-38 weeks of pregnancy. Sessions alternate between land and aquatic settings and include mobility, lumbopelvic stabilization, core and multifidus strengthening, and safe aerobic training. If pelvic floor dysfunction is identified at baseline using the Pelvic Floor Distress Inventory (PFDI-20), participants will also receive individualized pelvic floor rehabilitation (up to 9 sessions) focusing on pelvic floor muscle relaxation, strengthening, and coordination.

    Behavioral: Adapted Physical Activity · Behavioral: Pelvic Floor Rehabilitation

  • Active comparator
    Standard Care and Educational Flyer

    Participants receive standard prenatal care as provided by their healthcare providers. In addition, they are given a validated flyer containing international recommendations for safe physical activity during pregnancy. No supervised physiotherapy or structured exercise sessions are provided.

    Other: Standard Care (in control arm) · Other: Educational Flyer

Interventions

  • BehavioralAdapted Physical Activity

    Group-based, weekly supervised 60-minute sessions including mobility, stability, strengthening, and aerobic exercises adapted for pregnancy and pelvic girdle pain.

  • BehavioralPelvic Floor Rehabilitation

    Individual physiotherapy sessions using the PERFECT scheme to assess and retrain pelvic floor muscle function, including education, manual therapy, relaxation, and strengthening

  • OtherStandard Care (in control arm)

    Usual prenatal care provided by obstetricians or midwives according to local practice.

  • OtherEducational Flyer

    Written information with evidence-based international guidelines on physical activity during pregnancy.

06

What researchers measure

Primary outcomes

  1. Pain Intensity (Visual Analog Scale, VAS)

    Pain intensity related to pelvic girdle pain measured on a 10 cm Visual Analog Scale (0 = no pain, 10 = worst imaginable pain).

    Time frame: Baseline (≤27 weeks gestation), 36-38 weeks gestation and 3 months postpartum.

  2. Functional Impact of Pelvic Girdle Pain (Pelvic Girdle Questionnaire, PGQ)

    Functional disability and symptoms assessed with the 25-item Pelvic Girdle Questionnaire (PGQ, score range 0-100; higher scores indicate greater disability).

    Time frame: Baseline, Gestational Weeks 36-38 and 3 months postpartum.

Secondary outcomes

  1. Physical Activity (Pregnancy Physical Activity Questionnaire, PPAQ)

    Self-reported activity levels assessed with the Pregnancy Physical Activity Questionnaire (PPAQ), covering household, occupational, sports/exercise, and transportation domains. Scores reported as MET-hours/week.

    Time frame: Baseline, Gestational Weeks 36-38 and 3 months postpartum.

  2. Pelvic Symptoms (Pelvic Floor Distress Inventory, PFDI-20)

    Pelvic floor symptoms assessed with the 20-item PFDI-20 questionnaire (score range 0-300; higher scores indicate more severe symptoms).

    Time frame: Baseline, Gestational Weeks 36-38 and 3 months postpartum.

  3. Pelvic Floor Function (PERFECT Scheme)

    Clinical evaluation of pelvic floor muscle function using the PERFECT scheme (Power, Endurance, Repetitions, Fast contractions, Every Contraction Timed), assessed by digital palpation.

    Time frame: Baseline and Gestational Weeks 36-38

  4. Adherence to Intervention

    Proportion of participants in the intervention arm who attend ≥75% of scheduled sessions.

    Time frame: During pregnancy until 36-38 weeks gestation.

  5. Acceptability of Intervention

    Participant satisfaction assessed with a post-intervention questionnaire (Likert scale 0-10) regarding the usefulness, feasibility, and comfort of the intervention.

    Time frame: At 36-38 weeks gestation.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — At this stage, no formal plan for IPD sharing has been established. De-identified individual participant data may be made available upon reasonable request to the sponsor (Haute École de Santé Vaud, HESAV) after publication of the main trial results. Any data sharing will require a data sharing agreement and approval by the principal investigator (Professor Jeanne BERTUIT)

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186504
Lead sponsor
Haute Ecole de Santé Vaud
Collaborators
La Tour Hospital
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Sep 30, 2025 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Sep 22, 2025

Study contacts

Jeanne BERTUIT, Associate Professor
Contact
jeanne.bertuit@hesav.ch
+41 21 316 81 33
Tara REMAN, Assistant Professor
Contact
tara.reman@hesav.ch
+41 21 556 64 54

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion